# Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia

> **NCT06748105** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Lauro Fabián Amador Medina** · enrollment: 38 (estimated)

## Conditions studied

- Dapagliflozin (Forxiga)
- Hyperglycaemia
- Glucocorticoid

## Interventions

- **DRUG:** Dapagliflozin (DAPA)

## Key facts

- **NCT ID:** NCT06748105
- **Lead sponsor:** Lauro Fabián Amador Medina
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2024-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06748105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06748105, "Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06748105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*